vitamin D status in school children

Effects of different doses of oral Cholecalciferol on serum1-25(OH)D during Fall and Winter in school children of Taleghan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201009131681N2

Enrollment

210

Registered

2010-09-15

Start date

2007-07-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Status of vitamin D in school children. Vitamin D deficiency, unspecified

Interventions

Intervention 1: 50 000 units of oral vitamin D3 monthly during 6 months. Intervention 2: 50 000 units of oral vitamin D3 bimonthly during 6 months. Intervention 3: Placebo monthly, similar to the real

Treatment - Drugs

Placebo

50 000 units of oral vitamin D3 monthly during 6 months

50 000 units of oral vitamin D3 bimonthly during 6 months

Placebo monthly, similar to the real drug in shape for 6 months

Eligibility

Sex/Gender

All

Age

14 Years to 20 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: healthy active students Exclusion criteria: Presence of disorders affecting bone metabolism, taking supplements or drugs affecting bone metabolism

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum levels of 1-25(OH)D. Timepoint: at the begining, middle, and end of the study. Method of measurement: RIA.	—

Secondary

Measure	Time frame
Serum levels of bone specific alkaline phosphatase. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: IRA.;Serum levels of Calcium. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: IRA.;Serum levels of 25-OHD. Timepoint: at the begining, middle, and end of the study. Method of measurement: RIA.;Serum levels of iPTH. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: IRA.;Serum levels of osteocalcin. Timepoint: At the begining, middle, and end of the study. Method of measurement: IRA.;24 hour urine c-telopeptide. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: IRA.	—

Measure

Time frame

Serum levels of bone specific alkaline phosphatase. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: IRA.;Serum levels of Calcium. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: IRA.;Serum levels of 25-OHD. Timepoint: at the begining, middle, and end of the study. Method of measurement: RIA.;Serum levels of iPTH. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: IRA.;Serum levels of osteocalcin. Timepoint: At the begining, middle, and end of the study. Method of measurement: IRA.;24 hour urine c-telopeptide. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: IRA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli A.M.Ghazi MD

Shahid Beheshti University of Medical Sciences

ghazi@endocrine.ac.ir+98 21 2240 9309

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026